Cullinan Oncology takes a unique approach to drug development through the prism of modern day portfolio management.

Cullinan was formed to capitalize on the latest scientific breakthroughs by advancing a growing portfolio of innovative, early-stage assets.


  • Unique, cost efficient business model upends traditional drug development
  • Dynamic portfolio management distributes risk, streamlines development and enhances optionality
  • Veteran leadership team of oncology researchers, biopharma executives and experienced entrepreneurs


  • Capitalize on recent scientific breakthroughs
  • Assets sourced internally through Cullinan dry lab or externally through business, academic and pharma collaborations
  • Diversification across platforms, mechanisms and modalities